February 11, 2026

What Are the Top Reasons Equity Analysts Cease Coverage of Biotechs? (And Is It Because Their Bank Was Left Out of a Deal?)

A perennial question from my clients is this: “If we don’t include XYZ bank in our next financing, will they stop publishing research on us?”

It’s an understandable fear because there is no direct contract between the research department of any given bank and the biotechs that bank brings to market.

Yes, coverage is “assured” through including a bank in your IPO syndicate (though not necessarily positive coverage – analysts’ opinions and recommendations remain their own and cannot legally be influenced), but there is never a specified time for how long coverage will last for, or a defined mechanism for how or when it will come to an end. Especially in instances where a bank is excluded from subsequent financing rounds.

Given the above, we thought it would be insightful to look at the most common reasons given for why banks cease coverage of biotech stocks.

What can we know about reasons for dropping coverage?

FINRA Rule 2241 (Research Analysts and Research Reports) (f) (Termination of Coverage) states that:

“A member must promptly notify its customers if it intends to terminate coverage of a subject company. Such notice must be made using the member’s ordinary means to disseminate research reports on the subject company to its various customers. The notice must be accompanied by a final research report, comparable in scope and detail to prior research reports, and include a final recommendation or rating. If impracticable to provide a final research report, recommendation or rating, a member must disclose to its customers its reason for terminating coverage.”

Source: finra.org

In compliance with the above, most banks now issue a research note when they cease coverage of a biotech, more or less stating their reasoning. We decided to take a sample of these “cessation of coverage” notes to analyze.

We looked at the period October 1, 2024 – December 31, 2024, i.e., 4Q’24.

The banks whose biotech/pharma research we scoured (in alphabetical order) were: Barclays, BofA, BTIG, Canaccord, Cantor, Chardan, Evercore, Goldman Sachs, Guggenheim, H.C. Wainwright, J.P. Morgan, Jefferies, JMP Securities (Citizens), Ladenburg, Leerink, Mizuho, Morgan Stanley, Needham, Oppenheimer, Piper Sandler, Raymond James, RBC, Roth, Stifel, TD Cowen, Truist, Wedbush, Wells Fargo, and William Blair.

So, what are the most frequent reasons given for ceasing biotech coverage?

Reason Given	Count	%
Reallocation of Resources	57	43.8%
Analyst Departure	39	30.0%
Acquisition or Merger	26	20.0%
Not Given	4	3.1%
Company Bankruptcy	4	3.1%

Source: AlphaSense, New Street Investor Relations. N=130

What we found was that of the 130 cessation notes published in 4Q’24 (by the aforementioned banks), the majority of reasons given were fairly innocuous:

• “Reallocation of Resources” was the single biggest reason given, accounting for 57 of all the “dropped” biotechs (44%).
• “Analyst Departure” was behind 39 cessations (30%).
• “Acquisition or Merger” of the covered company was the reason for another 26 (20%).
• “Company Bankruptcy” was quoted 4 times (3%).

As such, on the face of it, in a combined 69 cases (53%, a majority), coverage stopped because the analyst left, or the biotech was taken over, or went bankrupt.

Cynics, however, will point to the combined 61 (47%) of cases – where no reason was given, or the bank decided to “reallocate resources” – as proof of something more nefarious (though obviously no bank is going to explicitly state they ceased coverage because they were excluded from a recent deal). But this is not clear cut.

When we dug into biotechs whose coverage was ended due to a “reallocation of resources,” we found a number of mistakes, and some highly understandable reasons.

Digging deeper into the numbers

Within the “reallocation of resources” category we found:

• Four more company bankruptcies.
• Five more mergers and acquisitions.
• One more analyst departure.

And uncovered two new underlying reasons for ending coverage:

• Clinical trial failure – mentioned 23 times.
• Poor company outlook – mentioned 4 times.

This new information makes the table we presented earlier look markedly different, once we include it.  

Underlying reasons for discontinuation of biotech coverage

Reason Given	Count	%
Analyst Departure	40	30.8%
Acquisition or Merger	31	23.8%
Trial Failure	23	17.7%
Reallocation of Resources	20	15.4%
Company Bankruptcy	8	6.2%
Poor Company Outlook	4	3.1%
Not Given	4	3.1%

Source: AlphaSense, New Street Investor Relations. N=130.

It’s about how you run your biotech, not how you pick your financing syndicate

• Now, even if we assume that every “Reallocation of Resources” and “Not Given” discontinuation of coverage was done because a bank felt slighted from being left out of a financing, this only represented approximately 1/5 (a combined 18.5%) of all discontinuations of coverage.
• Roughly 1/4 of discontinuations (23.8%) occurred because the biotech was taken over.
• Another 1/4 of discontinuations (27%) took place because of negative news from the biotech (trial failure, poor company outlook, or company bankruptcy).
• Meanwhile, almost 1/3 took place because a biotech’s covering analyst left the bank.

All of which points to the central role of the analyst (rather than the bank’s management) in choosing which stocks to maintain coverage of. In instances where coverage is no longer necessary (takeover) or where the analyst has been burned (trial failure, bankruptcy, poor company outlook), the data points to the analyst deciding it’s better to focus his or her attention elsewhere.

Importantly, operational outcomes (both positive and negative) for a biotech were almost three times more likely to lead to a cessation of coverage than leaving a bank out of a financing (assuming the underlying reason for an unexplained “Reallocation of Resources” or reason “Not Given” for ceasing coverage is indicative of an aggrieved bank).